Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review

Ouali, Cid Ould; Ladjouzi, Nadia; Tamas, Khidher; Raveloson, Hendriniaina; Hassen, Jihene Ben; Omeiri, Nesrine El; Zouloumis, Georges; Zoabi, Mohamed Moataz Al; Asadi, Muneer; Jhouri, Aziza; Schlatter, Joël

doi:10.3390/geriatrics7010022

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tocilizumab (TCZ) and sarilumab, both of which are monoclonal antibodies that block IL-6, showed benefits in COVID-19 when given early [ 77 ]. They demonstrated a significant reduction in mortality in the highest risk patients including those with a high C-reactive protein (CRP) level, and in the elderly where outcomes are worse [ 78 ]. Despite this and the fact that it quickly resolves clinical manifestations including fever and oxygen saturation, there is still controversy around it as a phase 3 randomized trial of hospitalized patients with severe COVID-19 pneumonia did not show benefit in clinical status and/or mortality rates at 28 days [ 79 ].…”

Section: Reviewmentioning

confidence: 99%

Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology

Bankole¹,

Nwaonu²,

Saeed³

2023

Cureus

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has had a significant impact on the healthcare field that resulted in changes to the way safe and effective medical care is delivered. The effects range from service disruption including ambulatory clinic closure due to both patient and provider concerns, to lack of capacity in hospital services. In rheumatology, there were other effects including viral infection-related autoantibody production, concerns about the use of systemic immunosuppression in the presence of an infectious pandemic and even concerns for viral infection-induced flares of rheumatic disease.Coronavirus disease 2019 (COVID-19) led to the rapid adoption of innovative technologies that permitted the introduction and increased use of telemedicine via a number of platforms. Rapid discoveries and innovations led to the development of diagnostic and therapeutic agents in the management of COVID-19. Scientific advancement and discoveries around COVID-19 infection, symptoms, autoantibody production, chronic sequela and the repurposing of rheumatic immunosuppressive agents led to improved survival and an expanded role for the rheumatologist.Rheumatologists may sometimes be involved in the diagnosis and management of the hospitalized COVID-19 patient. In the ambulatory clinic, a rheumatologist also helps to differentiate between symptoms of long COVID and those of systemic autoimmune rheumatic disease (SARD). Rheumatologists must also grapple with the concerns related to immunosuppressive therapy and the risk of COVID-19 infections. In addition, there are concerns around vaccine effectiveness in people with SARD and those on immunosuppressive medications. Although the SARS-CoV-2 pandemic and the effects on healthcare resulted in difficulties, both patients and providers have risen to the challenge. The long-term outcome of COVID-19 for the medical system and rheumatologists in particular is not yet fully understood and will need further study. This review concentrates on the changing role of the rheumatologists, improved understanding of rheumatic disease and immunosuppressive therapies in the wake of the pandemic and how this has led to an improvement in the care of patients with COVID-19.

show abstract

Section: Reviewmentioning

confidence: 99%

Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology

Bankole¹,

Nwaonu²,

Saeed³

2023

Cureus

View full text Add to dashboard Cite

show abstract

Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance

et al. 2023

View full text Add to dashboard Cite

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be asymptomatic or cause a disease (COVID-19) characterized by different levels of severity. The main cause of severe COVID-19 and death is represented by acute (or acute on chronic) respiratory failure and acute respiratory distress syndrome (ARDS), often requiring hospital admission and ventilator support.The molecular pathogenesis of COVID-19-related ARDS (by now termed c-ARDS) is still poorly understood. In this review we will discuss the genetic susceptibility to COVID-19, the pathogenesis and the local and systemic biomarkers correlated with c-ARDS and the therapeutic options that target the cell signalling pathways of c-ARDS.

show abstract

Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review

Cited by 2 publications

References 24 publications

Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology

Impact of SARS-CoV-2/COVID-19 on Provision of Medical Care to Patients With Systemic Autoimmune Rheumatic Disease and the Practice of Rheumatology

Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance

Contact Info

Product

Resources

About